CN119280227A - 治疗与s1p1受体相关的病症的方法 - Google Patents

治疗与s1p1受体相关的病症的方法 Download PDF

Info

Publication number
CN119280227A
CN119280227A CN202411419528.2A CN202411419528A CN119280227A CN 119280227 A CN119280227 A CN 119280227A CN 202411419528 A CN202411419528 A CN 202411419528A CN 119280227 A CN119280227 A CN 119280227A
Authority
CN
China
Prior art keywords
compound
individual
administered
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411419528.2A
Other languages
English (en)
Chinese (zh)
Inventor
T·C·阮-克利里
L·M·阿塞维多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN119280227A publication Critical patent/CN119280227A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CN202411419528.2A 2019-10-01 2020-09-30 治疗与s1p1受体相关的病症的方法 Pending CN119280227A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962909113P 2019-10-01 2019-10-01
US62/909,113 2019-10-01
CN202080076189.6A CN115038438A (zh) 2019-10-01 2020-09-30 治疗与s1p1受体相关的病症的方法
PCT/US2020/053642 WO2021067506A1 (en) 2019-10-01 2020-09-30 Methods of treating conditions related to the s1p1 receptor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080076189.6A Division CN115038438A (zh) 2019-10-01 2020-09-30 治疗与s1p1受体相关的病症的方法

Publications (1)

Publication Number Publication Date
CN119280227A true CN119280227A (zh) 2025-01-10

Family

ID=75337529

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411419528.2A Pending CN119280227A (zh) 2019-10-01 2020-09-30 治疗与s1p1受体相关的病症的方法
CN202080076189.6A Pending CN115038438A (zh) 2019-10-01 2020-09-30 治疗与s1p1受体相关的病症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080076189.6A Pending CN115038438A (zh) 2019-10-01 2020-09-30 治疗与s1p1受体相关的病症的方法

Country Status (12)

Country Link
US (1) US20220347158A1 (cg-RX-API-DMAC7.html)
EP (1) EP4037678A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022550458A (cg-RX-API-DMAC7.html)
KR (1) KR20220074913A (cg-RX-API-DMAC7.html)
CN (2) CN119280227A (cg-RX-API-DMAC7.html)
AU (1) AU2020360413A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022005999A2 (cg-RX-API-DMAC7.html)
CA (1) CA3156182A1 (cg-RX-API-DMAC7.html)
IL (1) IL291654A (cg-RX-API-DMAC7.html)
MX (1) MX2022003982A (cg-RX-API-DMAC7.html)
TW (1) TW202114656A (cg-RX-API-DMAC7.html)
WO (1) WO2021067506A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023135506A1 (en) 2022-01-13 2023-07-20 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104311472B9 (zh) * 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
EP2528894A1 (en) * 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) * 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
KR20190113955A (ko) * 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법

Also Published As

Publication number Publication date
US20220347158A1 (en) 2022-11-03
MX2022003982A (es) 2022-07-12
KR20220074913A (ko) 2022-06-03
WO2021067506A1 (en) 2021-04-08
JP2022550458A (ja) 2022-12-01
TW202114656A (zh) 2021-04-16
AU2020360413A1 (en) 2022-04-14
CA3156182A1 (en) 2021-04-08
AU2020360413A8 (en) 2022-04-21
EP4037678A4 (en) 2023-11-29
CN115038438A (zh) 2022-09-09
EP4037678A1 (en) 2022-08-10
IL291654A (en) 2022-05-01
BR112022005999A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
JP5882208B2 (ja) ラキニモドによるクローン病の治療
EP3908276B1 (en) Methods of treating conditions related to the s1p1 receptor
JP2017200926A (ja) 第一選択の抗TNEα療法に失敗したクローン病患者を治療するためのラキニモドの使用
EP3119401A2 (en) Cenicriviroc for the treatment of fibrosis
WO2022099150A1 (en) Methods of treating conditions related to the s1p1 receptor
JP2022511788A (ja) S1p1受容体に関連する状態を治療する方法
WO2021163355A1 (en) Formulations and methods of treating conditions related to the s1p1 receptor
TW202114656A (zh) 治療與s1p1 受體相關之病況的方法
CN121712505A (zh) 使用因子b抑制剂的方法
RU2821032C1 (ru) Способы лечения заболеваний, связанных с рецептором s1p1
Kobata et al. Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study
WO2023214312A1 (en) Methods of treating atopic dermatitis with etrasimod
AU2023203085A1 (en) Methods of treating conditions related to the S1P1 receptor
Yonkof et al. Colchicine toxicity in a patient with chronic urticaria masquerading with features of hemophagocytic lymphohistiocytosis
HK40116740A (en) Methods of treating conditions related to the s1p1 receptor
JP2014527513A (ja) 早漏症治療用の薬学組成物および早漏症治療方法
Grover et al. Prevention of Adverse Outcomes and Treatment Side Effects in Patients with Neuromuscular Disorders
WO2025184133A1 (en) Methods of treating chronic graft versus host disease with belumosudil after ceasing administration of ruxolitinib
HK40103286A (en) Methods of treating conditions related to the s1p₁ receptor
HK40109901A (en) Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment
HK40063670B (en) Methods of treating conditions related to the s1p1 receptor
HK40063670A (en) Methods of treating conditions related to the s1p1 receptor
WO2025167710A1 (zh) 三稠环化合物在制备预防和/或治疗炎性疾病药物中的应用
CN118541151A (zh) 与激素治疗组合的用于治疗s1p1受体相关病症的伊曲莫德
EP3094330A1 (en) Treatment of crohn's disease using low doses of laquinimod

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination